APLS
Apellis Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -15.4% ·
share flow +4.7% ·
net new positions -18.2%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 99 | +3 | 79.10M | $3.12B | +14 | −12 |
| Q4 2025 | 97 | +1 | 73.39M | $1.84B | +2 | — |
| Q3 2025 | 19 | +1 | 50.24M | $1.14B | +1 | −1 |
| Q2 2025 | 16 | +2 | 43.69M | $756.24M | +2 | — |
| Q1 2025 | 11 | -2 | 24.93M | $545.30M | +1 | −3 |
| Q4 2024 | 13 | +2 | 23.82M | $760.24M | +3 | −1 |
| Q3 2024 | 10 | +2 | 20.37M | $587.46M | +2 | — |
| Q2 2024 | 8 | — | 21.17M | $811.69M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 12.30M | +4.3% | $269.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 12.30M | +4.3% | $269.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 12.30M | +4.3% | $269.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 12.30M | +4.3% | $269.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 12.30M | +4.3% | $269.07M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 4.08M | +119.6% | $89.17M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 4.08M | +119.6% | $89.17M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 4.08M | +119.6% | $89.17M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 4.08M | +119.6% | $89.17M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 4.08M | +119.6% | $89.17M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 11 | State Street Global Advisors ✦ (passive) | 3.94M | -12.9% | $86.20M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 1.95M | +6.0% | $42.66M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Geode Capital Management ✦ (passive) | 1.95M | +6.0% | $42.66M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Norges Bank ✦ (passive) | 1.57M | +44.9% | $34.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Millennium Management ✦ | 451.97K | -21.5% | $9.88M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 262.90K | New | $5.75M | 0.0% | New | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 224.10K | +99.3% | $4.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 224.10K | +99.3% | $4.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 90.70K | -74.7% | $1.98M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 34.28K | +41.1% | $749,813 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | Marshall Wace ✦ | 23.57K | -72.4% | $515,563 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $5.75M | 0.0% |
Exited
| Point72 Asset Management | $40.46M | was 0.1% |
| Renaissance Technologies | $8.68M | was 0.0% |
| D. E. Shaw & Co. | $638,200 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 320 holders, 137.95M shares, $5.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.